|
Cofactors
|
Present
|
Absent
|
Relative risk (95% CI)
|
P-value
|
|---|
|
GUD
|
2/5 (40%)
|
25/65 (38%)
|
1.04 (0.34 – 3.18)
|
0.68
|
|
Anti HSV-2 IgG* (Kalon test)
|
11/27 (41%)
|
7/32 (22%)
|
1.86 (0.84 – 4.13)
|
0.19
|
|
HIV
|
3/7 (43%)
|
23/59 (39%)
|
1.1 (0.44 – 2.74)
|
0.83
|
|
BV
|
14/35 (40%)
|
13/35 (37%)
|
1.08 (0.60 – 1.95)
|
1.00
|
|
C. trachomatis
|
5/7 (71%)
|
22/63 (35%)
|
2.05 (1.15 – 3.64)
|
0.14
|
|
Hepatitis B
|
5/8 (63%)
|
22/54 (41%)
|
1.53 (0.82 – 2.87)
|
0.44
|
|
Candida
|
9/29 (31%)
|
18/41 (44%)
|
0.71 (0.37 – 1.35)
|
0.40
|
|
T. vaginalis
|
3/7 (43%)
|
24/63 (38%)
|
1.13 (0.45 – 2.80)
|
0.86
|
- * Comparison with HSV-2 only. P values calculated by χ2 test
